Cargando…

PI-RADS v2.1 Combined With Prostate-Specific Antigen Density for Detection of Prostate Cancer in Peripheral Zone

PURPOSE: To evaluate the diagnostic performance of combining the Prostate Imaging Reporting and Data System (PI-RADS) scoring system v2.1 with prostate-specific antigen density (PSAD) to detect prostate cancer (PCa). METHODS: A total of 266 participants with suspicion of PCa underwent multiparametri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wen, Jing, Tang, Tingting, Ji, Yugang, Zhang, Yilan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024291/ https://www.ncbi.nlm.nih.gov/pubmed/35463349 http://dx.doi.org/10.3389/fonc.2022.861928

Ejemplares similares

Use of Radiomics to Improve Diagnostic Performance of PI-RADS v2.1 in Prostate Cancer
por: Li, Mou, et al.
Publicado: (2021)

Evaluating the Utility of Prostate-Specific Antigen Density in Risk Stratification of PI-RADS 3 Peripheral Zone Lesions on Non-Contrast-Enhanced Prostate MRI: An Exploratory Single-Institution Study
por: Kalchev, Emilian
Publicado: (2023)

Combining prostate-specific antigen density with prostate imaging reporting and data system score version 2.1 to improve detection of clinically significant prostate cancer: A retrospective study
por: Lei, Yin, et al.
Publicado: (2022)

Combination of PI-RADS score and PSAD can improve the diagnostic accuracy of prostate cancer and reduce unnecessary prostate biopsies
por: Wang, Changming, et al.
Publicado: (2022)

Metabolomics Profiling Discriminates Prostate Cancer From Benign Prostatic Hyperplasia Within the Prostate-Specific Antigen Gray Zone
por: Xu, Bei, et al.
Publicado: (2021)

Machine learning-based analysis of a semi-automated PI-RADS v2.1 scoring for prostate cancer
por: Singh, Dharmesh, et al.
Publicado: (2022)

Diagnostic performance of PI-RADS version 2.1 compared to version 2.0 for detection of peripheral and transition zone prostate cancer
por: Rudolph, Madhuri Monique, et al.
Publicado: (2020)

Optimizing prostate cancer accumulating model: combined PI-RADS v2 with prostate specific antigen and its derivative data
por: Lu, Yuan-Fei, et al.
Publicado: (2019)

Improving the detection rate of prostate cancer in the gray zone of PI-RADS v2 and serum tPSA by using prostate-specific antigen–age volume
por: Lu, Yuan-Fei, et al.
Publicado: (2019)

MRI Based Radiomics Compared With the PI-RADS V2.1 in the Prediction of Clinically Significant Prostate Cancer: Biparametric vs Multiparametric MRI
por: Chen, Tong, et al.
Publicado: (2022)

Study of iron metabolism based on T2* mapping sequences in PI-RADS 3 prostate lesions
por: D, Wenhao, et al.
Publicado: (2023)

Utility of Clinical–Radiomic Model to Identify Clinically Significant Prostate Cancer in Biparametric MRI PI-RADS V2.1 Category 3 Lesions
por: Jin, Pengfei, et al.
Publicado: (2022)

Transition Zone Prostate Specific Antigen Density Improves Prostate Cancer Detection in Iranian Men
por: Nowroozi, Mohammadreza, et al.
Publicado: (2015)

Peripheral zone prostate-specific antigen density: an effective parameter for prostate cancer prediction in men receiving 5α-reductase inhibitors
por: Koo, Kyo Chul, et al.
Publicado: (2013)

Transverse prostate maximum sectional area can predict clinically significant prostate cancer in PI-RADS 3 lesions at multiparametric magnetic resonance imaging
por: Gaudiano, Caterina, et al.
Publicado: (2023)

Development and Validation of a Radiomics Nomogram for Predicting Clinically Significant Prostate Cancer in PI-RADS 3 Lesions
por: Li, Tianping, et al.
Publicado: (2022)

Isolated brain metastasis of prostate carcinoma in the setting of normal prostate specific antigen
por: Campagna, Justin P., et al.
Publicado: (2018)

Assessing the validity of Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) scoring system in diagnosis of peripheral zone prostate cancer
por: Dola, Eman F., et al.
Publicado: (2017)

Development, comparison, and validation of four intelligent, practical machine learning models for patients with prostate-specific antigen in the gray zone
por: Liu, Taobin, et al.
Publicado: (2023)

New model of PIRADS and adjusted prostate-specific antigen density of peripheral zone improves the detection rate of initial prostate biopsy: a diagnostic study
por: Huang, Chen, et al.
Publicado: (2022)

A nomogram based on PI-RADS v2.1 and clinical indicators for predicting clinically significant prostate cancer in the transition zone
por: Wei, Chaogang, et al.
Publicado: (2021)

Quantitative Evaluation of Apparent Diffusion Coefficient Values, ISUP Grades and Prostate-Specific Antigen Density Values of Potentially Malignant PI-RADS Lesions
por: Spadarotto, Nadine, et al.
Publicado: (2023)

Prostate-Specific Antigen Bounce Following Stereotactic Body Radiation Therapy for Prostate Cancer
por: Vu, Charles C., et al.
Publicado: (2014)

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2021)

Focal therapy of prostate cancer: Assessment with prostate-specific membrane antigen (PSMA) imaging
por: Topoozian, Mark, et al.
Publicado: (2023)

Inter-reader agreement of the prostate imaging reporting and data system version v2.1 for detection of prostate cancer: A systematic review and meta-analysis
por: Wen, Jing, et al.
Publicado: (2022)

Primary follicular lymphoma of the prostate presenting with elevated PSA and a PI-RADS 3 lesion on MRI: A case report
por: Jia, Hanna, et al.
Publicado: (2022)

New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen
por: Cimadamore, Alessia, et al.
Publicado: (2018)

Clinical Implications of Nadir Serum Prostate-Specific Antigen Levels After Transurethral Enucleation of the Prostate
por: Cheng, Yung-Ting, et al.
Publicado: (2022)

The role of prostate-specific antigen in the osteoblastic bone metastasis of prostate cancer: a literature review
por: Zhang, Xu, et al.
Publicado: (2023)

Prostate multi-parametric magnetic resonance imaging appearance of diffuse adenosis of the peripheral zone (DAPZ)
por: Lowe, Avanka W., et al.
Publicado: (2022)

Differences in the pathogenetic characteristics of prostate cancer in the transitional and peripheral zones and the possible molecular biological mechanisms
por: Yu, Xudong, et al.
Publicado: (2023)

The performance characteristics of prostate-specific antigen and prostate-specific antigen density in Chinese men
por: Teoh, Jeremy YC, et al.
Publicado: (2017)

The Application of Biopsy Density in Transperineal Templated-Guided Biopsy Patients With PI-RADS<3
por: Zhu, Hai, et al.
Publicado: (2022)

Value of an online PI-RADS v2.1 score calculator for assessment of prostate MRI
por: Barth, Borna K., et al.
Publicado: (2021)

Age and Prostate-Specific Antigen Level Prior to Diagnosis Predict Risk of Death from Prostate Cancer
por: MacKintosh, F. Roy, et al.
Publicado: (2016)

Values and preferences of men for undergoing prostate-specific antigen screening for prostate cancer: a systematic review
por: Vernooij, Robin W M, et al.
Publicado: (2018)

Influence of Tumor Burden on Serum Prostate-Specific Antigen in Prostate Cancer Patients Undergoing Radical Prostatectomy
por: Mandel, Philipp, et al.
Publicado: (2021)

Survival in Patients With Metastatic Prostate Cancer Undergoing Radiotherapy: The Importance of Prostate-Specific Antigen-Based Stratification
por: Tian, Zijian, et al.
Publicado: (2021)

Diagnostic performance of transperineal prostate targeted biopsy alone according to the PI-RADS score based on bi-parametric magnetic resonance imaging
por: Noh, Tae Il, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c50h51f1khb2d196kp9nkcns41